First Department of Medicine-Cardiology, University Medical Centre Mannheim, Mannheim, Germany and DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Mannheim, Germany.
Department of Neurology, University Medical Centre Mannheim, University of Heidelberg, Germany.
J Crit Care. 2018 Apr;44:39-44. doi: 10.1016/j.jcrc.2017.10.009. Epub 2017 Oct 12.
Pulmonary embolism (PE) is a frequently occurring complication in critically ill patients. Simultaneous occurrence of PE and life-threatening bleeding, may render medical anticoagulation impossible. For these patients, inferior vena cava filters (IVCF) present a valuable therapeutic alternative. The Angel® catheter is a novel IVCF that provides temporary protection from PE and is implanted at bedside. The primary objective of the European Angel® catheter registry is to evaluate the safety and efficacy of this IVCF.
The European Angel® catheter registry is an observational, multi-centre registry. Patients from four countries and eight sites that have undergone Angel® catheter implantation between March 2013 and February 2017 were enrolled.
A total of 114 critically ill patients were included. The main indication for implantation was a high-risk for PE in combination with contraindications for anticoagulation (69.3%). One clinically non-significant PE (0.9%) occurred in a patient with an indwelling Angel® catheter. No cases of catheter associated serious complications were observed.
Data shows that the Angel® catheter is a safe and effective approach to overcome the acute phase of critically ill patients with a high risk for the development of PE or an established PE, when an anticoagulation therapy is contraindicated.
肺栓塞（PE）是危重症患者中经常发生的并发症。同时发生的 PE 和危及生命的出血可能使医学抗凝治疗变得不可能。对于这些患者，下腔静脉滤器（IVCF）是一种有价值的治疗选择。Angel®导管是一种新型 IVCF，可提供临时的 PE 保护，并在床边植入。欧洲 Angel®导管注册研究的主要目的是评估这种 IVCF 的安全性和疗效。
欧洲 Angel®导管注册研究是一项观察性、多中心注册研究。2013 年 3 月至 2017 年 2 月期间，来自四个国家和八个地点的植入 Angel®导管的 114 名危重症患者被纳入研究。
共纳入 114 例危重症患者。植入的主要适应证是 PE 风险高合并抗凝禁忌（69.3%）。在一名留置 Angel®导管的患者中发生了一例临床无意义的 PE（0.9%）。未观察到与导管相关的严重并发症。
数据表明，当抗凝治疗禁忌时，Angel®导管是一种安全有效的方法，可用于治疗高危发生 PE 或已确诊 PE 的危重症患者的急性阶段。
